“Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report:
Companies across the globe are diligently working toward developing novel Alpha-1 Antitrypsin Deficiency treatment therapies with a considerable amount of success over the years. Alpha-1 Antitrypsin Deficiency Key players such as – Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others, are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment
Alpha-1 Antitrypsin Deficiency Emerging therapies such as – APB-101, Belcesiran, PHP 303, ARO-AAT, and others are expected to have a significant impact on the Alpha-1 Antitrypsin Deficiency market in the coming years.
In April 2024, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company dedicated to harnessing the potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for the RestorAATion-2 trial of WVE-006. This is the company’s first-in-class RNA editing oligonucleotide, being developed to treat alpha-1 antitrypsin deficiency (AATD). WVE-006 is GalNAc-conjugated and administered subcutaneously, without the use of a lipid nanoparticle (LNP) delivery system.
In April 2024, Enlivex Therapeutics has announced promising topline safety and efficacy results from its Phase II clinical trial of Allocetra, an off-the-shelf cell therapy for sepsis. The randomized, placebo-controlled trial aims to identify the optimal dose of Allocetra when administered in conjunction with the standard care for sepsis caused by different infections.
In July 2023, Grifols successfully achieved the enrollment goal of 339 participants for the Phase III trial known as the Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), which aims to address emphysema. This placebo-controlled, double-blind, randomized study is structured to evaluate the safety and effectiveness of two doses of Alpha1-Proteinase inhibitor Prolastin-C—60mg/kg and 120mg/kg—administered once weekly in comparison to a placebo. The primary objective is to assess whether these doses can slow down the progression of lung tissue loss in patients with emphysema.
Alpha-1 Antitrypsin Deficiency Overview
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by a deficiency or malfunction of alpha-1 antitrypsin (AAT) protein, which is produced primarily in the liver. AAT is important for protecting the lungs from damage caused by enzymes produced by white blood cells, specifically neutrophil elastase.
Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight
Route of Administration
Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment
Alpha-1 Antitrypsin Deficiency Assessment by Product Type
Alpha-1 Antitrypsin Deficiency By Stage and Product Type
Alpha-1 Antitrypsin Deficiency Assessment by Route of Administration
Alpha-1 Antitrypsin Deficiency By Stage and Route of Administration
Alpha-1 Antitrypsin Deficiency Assessment by Molecule Type
Alpha-1 Antitrypsin Deficiency by Stage and Molecule Type
DelveInsight’s Alpha-1 Antitrypsin Deficiency Report covers around 4+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Further Alpha-1 Antitrypsin Deficiency product details are provided in the report. Download the Alpha-1 Antitrypsin Deficiency pipeline report to learn more about the emerging Alpha-1 Antitrypsin Deficiency therapies
Emerging Alpha-1 Antitrypsin Deficiency Drugs Under Different Phases of Clinical Development Include:
APB-101: Apic Bio
Belcesiran: Dicerna Pharmaceuticals
PHP 303: Peak Bio
ARO-AAT: Arrowhead Pharmaceuticals
Alpha-1 Antitrypsin Deficiency Pipeline Analysis:
The Alpha-1 Antitrypsin Deficiency pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency Treatment.
Alpha-1 Antitrypsin Deficiency key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alpha-1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alpha-1 Antitrypsin Deficiency drugs and therapies
Alpha-1 Antitrypsin Deficiency Pipeline Market Drivers
Increasing investment in the R&D activities for developing novel therapeutics
Rise in awareness among people
Alpha-1 Antitrypsin Deficiency Pipeline Market Barriers
Lack of diagnostic methods
Treatment dosage being poorly standardized
Scope of Alpha-1 Antitrypsin Deficiency Pipeline Drug Insight
Coverage: Global
Key Alpha-1 Antitrypsin Deficiency Companies: Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others
Key Alpha-1 Antitrypsin Deficiency Therapies: APB-101, Belcesiran, PHP 303, ARO-AAT, and others
Alpha-1 Antitrypsin Deficiency Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies
Alpha-1 Antitrypsin Deficiency Market Dynamics: Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers
Request for Sample PDF Report for Alpha-1 Antitrypsin Deficiency Pipeline Assessment and clinical trials
Table of Contents
1
Alpha-1 Antitrypsin Deficiency Report Introduction
2
Alpha-1 Antitrypsin Deficiency Executive Summary
3
4
Alpha-1 Antitrypsin Deficiency- Analytical Perspective In-depth Commercial Assessment
5
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics
6
Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase II/III)
7
Alpha-1 Antitrypsin Deficiency Mid Stage Products (Phase II)
8
Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase I)
9
Alpha-1 Antitrypsin Deficiency Preclinical Stage Products
10
Alpha-1 Antitrypsin Deficiency Therapeutics Assessment
11
Alpha-1 Antitrypsin Deficiency Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Alpha-1 Antitrypsin Deficiency Key Companies
14
Alpha-1 Antitrypsin Deficiency Key Products
15
Alpha-1 Antitrypsin Deficiency Unmet Needs
16
Alpha-1 Antitrypsin Deficiency Market Drivers and Barriers
17
Alpha-1 Antitrypsin Deficiency Future Perspectives and Conclusion
18
Alpha-1 Antitrypsin Deficiency Analyst Views
19
Appendix
20
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/